Europe's first AI native
supplement marketplace

Three layers of defensibility compound over time:

1. Operational lock-in. Once a brand routes formulation, production, compliance, and packaging through our platform, the switching costs become structural — not contractual. Migrating to a new CMO means re-validating all formulations, re-certifying with local regulators, and rebuilding the entire logistics chain.

2. AI native process layer. Our 12 AI agents automate ingredient validation (vs EFSA/FDA databases), dosage optimization, label content review, lead routing, quote generation, production scheduling, and client communication. Together, these let a 6-person team run processes that would normally require 15–20 FTEs. Replicating the agent stack requires both deep domain knowledge and production-grade AI infrastructure — not just prompt engineering.

3. Network effects from the marketplace. Every new brand on the platform adds demand signal data, formulation patterns, and packaging preferences that improve the AI matching engine for all participants. The more brands we onboard, the better our recommendations, pricing accuracy, and lead time estimates become — creating a compounding data advantage.

Competitors can build parts of this. Replicating all three layers simultaneously — while already serving live clients across 6+ EU markets — is the actual barrier.

We do not hold exclusive supplier agreements. Instead, we maintain a qualified, multi-source procurement matrix across the EU and global certified suppliers. This ensures redundancy, negotiation leverage, and compliance flexibility.

Sourcing is audited against GMP, ISO 22000, HACCP, and EFSA standards — with full CoA (Certificate of Analysis) traceability per batch. Our R&D and compliance modules validate each ingredient against current EFSA and local regulatory databases before any formulation is finalized.

We're raising €2M at a €20M pre-money valuation. Using our projected base-case revenue of ~€2.5M (PLN 10.4M at avg FX), that implies a forward revenue multiple of ~8.0×. Given comparable transactions in the European D2C health-tech / AI-CPG space (e.g. Vitable, Bioniq, and Nourished, which raised at 10–25× forward revenue), we believe this is a reasonable and founder-friendly valuation reflecting both our early traction (including 431% NRR) and the defensibility of our vertical AI platform.

Bottom-up decomposition of 2026 target (Base scenario):

• NUORO: €800K contracted ACV – production ramp-up confirmed, pending final volume sign-off
• REVO LIFE: SPV partnership (equity) — multi-product expansion in PL retail and pharma distribution
• Existing client expansion (NRR baseline ~64% logo retention): ~€1.5–2M from product line extensions and reorders
• New business pipeline (3 enterprise deals in final stages): €1–2M from ICP A/C/E prospects in legal review
• UAE pipeline conversion: €300–500K from GCC-based brands entering EU production
• Polish retail partnerships: ~€300–500K from domestic distribution channel

Total addressable from soft-committed + active pipeline: PLN 20–35M.
We guide to PLN 10–15M (Base) — significantly below bottom-up — because we discount aggressively for execution risk, timing slippage, and contract delays.

Revenue is generated through three integrated streams:

B2B manufacturing — contract production, private label, and white-label supplements. This is currently the core revenue driver, contributing ~80% of total income, with typical gross margins of 28–38%.

SaaS/platform fees — recurring access fees for the AI formulation engine, compliance tools, and ERP system. Currently in early monetization as part of the Marketplace MVP launch.

Marketplace commission — a take-rate on transactions processed through our B2B marketplace. This stream is in commercial pilot with first paying users in Q1 2026.

We focus on maximizing Net Revenue Retention (NRR) across all streams — currently at 431% for our best-performing cohort — driven by product expansion within existing accounts.

OTC (Over-the-Counter) registration:
Strategic. OTC supplements in Poland require URPL registration, which adds a compliance layer but opens higher-margin pharmacy distribution channels. We are currently in the registration pipeline for select SKUs via our R&D team. Expected first OTC-registered product: H2 2026.

Pet supplements:
A small-scale pilot in 2026 with one D2C pet brand (ICP B profile). Not a core thesis — exploratory only. Total bandwidth: <5% of management attention. If the unit economics validate, we may expand in 2027.

FDA / US market:
Strategic, not opportunistic. FDA facility certification process started Q1 2026, projected 12–18 months to completion. Once certified, US-based D2C supplement brands become accessible — a market segment most EU CMOs cannot serve. We expect first US-sourced revenue in late 2027.

US market entry is part of the Seed deployment plan: ~10% of round allocated to FDA process completion + initial US BD presence.

We have an active pipeline with several institutional and angel investors across Europe and the Middle East. We prefer not to disclose names at this stage without their explicit consent, but we're happy to share more details in a direct conversation. If you're interested, please reach out through the Contact section below or via email at jacek@suplement.io.

Path 1 — Strategic acquisition by global CMO (most likely). Catalent, Lonza, or large food/health corporates want digital platforms. Comparables: €100–300M exits in 2023–2025 for vertical SaaS + manufacturing in food/health. We need €30–50M ARR with strong unit economics.

Path 2 — PE-backed rollup. EU CMO consolidation is happening. We become the digital platform anchor. PE buyers typically pay 10–14× EBITDA at our scale.

We're building optionality, not committing to a single exit narrative.

We operate under the EU Food Supplements Directive (2002/46/EC) — stable, rarely amended. The most likely tightening areas:

• Health claims tightening — disadvantages small brands without R&D capacity (favors us)
• Novel ingredient rules — advantage CMOs with regulatory expertise
• Labelling requirements — cost burden small CMOs absorb less well

Regulatory tightening is generally accretive to our market share — increases barriers for small competitors. The genuine risk is country-specific rules (Italy vs Germany) — we manage this through country-specific formulation variants.

Top customer in 2025: ~25% of revenue. NUORO (ICP E) projected at ~18–22% in 2026.

We have a board-level policy: no single customer above 30% of annual revenue. Monitored monthly.

ICP E (funded D2C) segment = ~42% of total revenue across 4 clients. Loss of any single ICP E client would impact 8–13% — painful but absorbable within 2 quarters given pipeline depth and NRR mechanics.

Our concentration risk is actively managed through:
• Geographic diversification (6+ EU markets + UAE pipeline)
• ICP segment diversification (A through E)
• Marketplace platform driving long-tail customer acquisition at lower CAC

2024 closed near-breakeven (net profit PLN 1,168 — yes, literally). Current burn: ~€40K/month.

Pre-Seed cash covers current operations comfortably. We are not raising from distress — the Seed round is a growth accelerator, not a survival bridge.

Post-Seed projected burn: ~€80–140K/month (scaling from current team + first hires). €2M gives 16–20 months runway from close at full burn, plus revenue offset — effective runway 24+ months with base-case growth assumptions.

Series A target conditions: €2.5M+ ARR with 35%+ gross margin, 2+ geographies proving traction, and marketplace generating recurring platform revenue.

Operationally live — not a prototype. As of Q2 2026:

• Shopify vendor panel running in production — clients access orders, R&D requests, production status in real time
• Business Central integration handles scheduling, inventory, invoicing
• AI matching layer routes inquiries to product catalog and formulation database
• White label catalog orders processed through marketplace flow

Still in development: full self-serve checkout, AI-powered formulation wizard, SaaS billing layer. Commercial self-serve launch: H2 2026.

Live walkthrough and screenshots available in T2 vault or on a video call.

White label: Full IP ownership to client upon payment. Standard MSA clause.

Custom R&D: All IP assigned to client at contract execution — not conditionally. We retain operational knowledge only.

Co-development (ICP E): For deep partnerships (NUORO/FRESCO profile), SPV structures or equity arrangements — IP held in jointly-owned entity with clear exit mechanics. Our food law counsel handles these on monthly retainer.

Lesson learned: define IP framework before the first sample, not after. Now in our NDA template.

Success (primary): NUORO + FRESCO ramp to full production, 5+ new enterprise clients onboarded, marketplace reaches 50+ active brands, ARR crosses €2.5M+. Series A process begins from a position of strength.

Partial failure: One anchor client delays or underperforms, one geography ramps slower than planned, SaaS layer slips 6 months. Existing base still generates €1.5M+ ARR from NRR mechanics and client expansion. Runway extends 24+ months by adjusting hiring pace. No existential risk.

Hard failure (requires simultaneous catastrophes): Both NUORO and FRESCO fall through AND zero new enterprise clients close AND marketplace generates no traction. Even then: 2025 base generates ~€1M ARR, burn drops to €40K/month (pre-Seed operating mode), runway exceeds 24 months.

Every hire in the plan maps to a specific bottleneck with a defined payback timeline. The full hiring plan is available in the Hiring section above.

Production arbitrage. GMP-certified Polish CMOs produce at 35–50% lower cost than German, French, or Dutch facilities — identical EU standards.

Logistics. Warsaw: 2–3 day delivery to all EU markets. UAE ships direct. FDA certification removes US barrier.

Talent density. Biotech talent in Poland is deep and 40–50% cheaper than Western EU. Sebastian's network spans 14 years.

The actual risk: FX exposure (PLN-cost / EUR-revenue) — currently favorable, we model both scenarios. The "Polish = lower quality" perception dissolves on the first factory visit. Every funded D2C client who visited Warsaw has converted.